CD4 and neoplasm: As expected from their increased tumor numbers and tumor sizes, His-SjE16.7- and GST-SjE16.7-treated mice had a significant increase in the frequency of inflammatory myeloid cells (CD11b+) in their spleens but significantly lower frequency of CD4+ and CD8+ T cells (Figure 6).